Efficacy and Tolerability of Montelukast as a Therapeutic Agent for Severe Atopic Dermatitis in Adults

Nettis, Eustachio; Pannofino, A.; Fanelli, Margherita; Ferrannini, A.; Tursi, A.

doi:10.1080/000155502320323298

Cited by 24 publications

(9 citation statements)

References 4 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…P ruritus is a frequent and troublesome symptom in patients with chronic renal failure receiving hemodialysis. 1 However, it also may occur in patients on conservative uremia treatment or undergoing continuous ambulatory peritoneal dialysis. 1 For patients who are not candidates for kidney transplantation, broadband (BB) UVB phototherapy is considered by some authors as a treatment of choice.…”

Section: Discussionmentioning

confidence: 99%

“…1 However, it also may occur in patients on conservative uremia treatment or undergoing continuous ambulatory peritoneal dialysis. 1 For patients who are not candidates for kidney transplantation, broadband (BB) UVB phototherapy is considered by some authors as a treatment of choice. 2 However, little is known about the efficacy of narrowband (NB) UVB phototherapy in this condition.…”

Section: Discussionmentioning

confidence: 99%

“…Montelukast and zafirlukast have shown promising results in the treatment of both children and adults with AD, and the safety profile of these medicaments is excellent. [1][2][3][4][5] We wished to carry out a randomized, prospective, placebo-controlled study to determine whether oral treatment with the cysteinyl leukotriene antagonist montelukast would reduce the activity of moderate to severe AD in adults.…”

mentioning

confidence: 99%

See 2 more Smart Citations

Montelukast treatment of moderate to severe atopic dermatitis in adults: A randomized, double-blind, placebo-controlled trial

Veien

Busch-Sørensen

Stausbøl-Grøn

2005

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Section: Discussionmentioning

confidence: 99%

mentioning

confidence: 99%

See 1 more Smart Citation

Montelukast treatment of moderate to severe atopic dermatitis in adults: A randomized, double-blind, placebo-controlled trial

Veien

Busch-Sørensen

Stausbøl-Grøn

2005

Journal of the American Academy of Dermatology

View full text Add to dashboard Cite

“…Eustachio et al, 49 in a placebo-controlled study, treated 20 men with severe AD for 6 weeks and found a significant difference in Scoring Atopic Dermatitis (SCORAD) reduction between the montelukast group and the placebo group.…”

Section: Atopic Eczema/dermatitis Syndrome (Aeds)mentioning

confidence: 97%

Montelukast in allergic diseases beyond asthma

Leonardi

Marchese

Marseglia

et al. 2007

allergy asthma proc

View full text Add to dashboard Cite

Allergic diseases include a variety of different illnesses (rhinitis, conjunctivitis, asthma, urticaria, and dermatitis) in which the physiological and pathological basis is the release of chemical mediators such as histamine; platelet-activating factor; metabolites of arachidonic acid; and chemotactic factors from mastocytes, basophils, and eosinophils. The numerous drugs used for allergy treatment now include the new pharmacologic category of cysteinyl leukotriene (LT) antagonists. LTs are released from eosinophils, mast cells, and macrophages, interacting functionally in allergic reactions against a background of an imbalance between T-cell clones and resulting in preferential cytokine production following the T-helper 2 profile. Anti-LTs also have been used successfully by some authors to control rhinitis, atopic dermatitis, and urticaria. although additional controlled testing will be required, these applications broaden the possible range of treatments for allergic disease in all its many aspects.

show abstract

“…In 1998, one pilot study from the US reported that the LT antagonist zafirlukast successfully alleviated symptoms of AD [7]. Thereafter, four groups from the US, Italy, and Hong Kong reported that montelukast is an effective adjuvant treatment for AD [8][9][10][11]. Recently, Hon et al reported that montelukast at doses recommended for asthma treatment reduces disease severity and increases soluble CD14 levels in children with AD [12].…”

Section: Leukotriene Antagonistsmentioning

confidence: 98%

Emerging Treatment of Atopic Dermatitis

Hsu

Wang

2007

Clinic Rev Allerg Immunol

View full text Add to dashboard Cite

Atopic dermatitis is a chronically relapsing eczematous disease of the skin. A wide range of therapeutic regimens has been used for atopic dermatitis. A better understanding of its pathogenesis will also lead to the development of novel approaches to treating this disease. This article reviews the recent advances in allergen-specific sublingual immunotherapy and therapy with antileukotriene drugs, probiotics, mycophenolate mofetil, leflunomide, and intermittent fluticasone propionate ointment, which the authors expect will be clinically useful therapies in the near future.

show abstract

Efficacy and Tolerability of Montelukast as a Therapeutic Agent for Severe Atopic Dermatitis in Adults

Cited by 24 publications

References 4 publications

Montelukast treatment of moderate to severe atopic dermatitis in adults: A randomized, double-blind, placebo-controlled trial

Montelukast treatment of moderate to severe atopic dermatitis in adults: A randomized, double-blind, placebo-controlled trial

Montelukast in allergic diseases beyond asthma

Emerging Treatment of Atopic Dermatitis

Contact Info

Product

Resources

About